Compare FTHY & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FTHY | CTNM |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.6M | 489.4M |
| IPO Year | N/A | 2024 |
| Metric | FTHY | CTNM |
|---|---|---|
| Price | $13.59 | $15.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 83.5K | ★ 443.6K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 10.93% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.20 | $3.72 |
| 52 Week High | $14.87 | $16.91 |
| Indicator | FTHY | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 52.70 | 62.43 |
| Support Level | $13.21 | $10.86 |
| Resistance Level | $13.82 | $15.60 |
| Average True Range (ATR) | 0.13 | 1.25 |
| MACD | 0.02 | 0.43 |
| Stochastic Oscillator | 56.16 | 67.33 |
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.